Chymoral Forte Uses
Chymoral Forte (trypsin-chymotrypsin combination) is primarily indicated for managing inflammation and promoting tissue repair in acute surgical wounds, traumatic injuries, and inflammatory conditions, though the evidence supporting its clinical efficacy is limited and of low quality.
Primary Clinical Indications
Post-Surgical Wound Management
Chymoral Forte demonstrates its strongest evidence base in managing surgical wounds, particularly after orthopedic procedures. In a randomized trial, trypsin-chymotrypsin significantly reduced erythema (from 3.44 to 1.16 by day 10, p<0.01) and showed superior reduction in local irritation, wound discharge, edema, induration, and tenderness compared to serratiopeptidase and other enzyme combinations 1. The global assessment rated it as good to excellent in 88% of patients for efficacy 1.
Acute Inflammatory Conditions
The enzyme combination works by:
- Degrading damaged cells and necrotic material
- Inactivating inflammatory mediators and toxic products
- Restricting edema and pain through anti-inflammatory action 2
Specific Applications
Acute Hemorrhoids: When combined with heparin ointment as a topical paste, trypsin-chymotrypsin significantly reduced local pain, perianal edema, and tenderness in 67 patients with acutely inflamed hemorrhoids, with an average hospital stay of only 2 days 3.
Postoperative Pain Management: A 2023 randomized controlled trial found that trypsin-chymotrypsin (5mg each) demonstrated comparable efficacy to ibuprofen 600mg for managing postoperative pain after endodontic treatment, with no significant differences between groups 4.
Important Clinical Caveats
Evidence Quality Concerns
The provided FDA drug label 5 appears to describe a homeopathic sleep aid product, not the proteolytic enzyme preparation used clinically. This represents a critical labeling confusion that clinicians must recognize.
Mechanism of Action
Trypsin-chymotrypsin facilitates tissue repair through four overlapping phases: hemostasis, inflammation, proliferation, and remodeling 2. The enzymes help prevent progression from acute to chronic wounds, which are associated with significant morbidity and mortality.
Dosing Considerations
Based on clinical trials, the typical regimen is:
- 2 tablets orally three times daily for 7 days post-operatively 6
- Each tablet contains trypsin 48mg and chymotrypsin (doses vary by formulation)
Comparative Effectiveness
A 2025 study comparing trypsin-chymotrypsin to a combination of trypsin-bromelain-rutoside found non-significant differences in pain reduction (p=0.737) and wound healing (p=0.554), with both showing >85% reduction in pain scores 6.
Emerging Applications
Anti-tumor potential: Recent evidence suggests trypsinogen and chymotrypsinogen may sensitize cancer stem cells, potentially enhancing chemotherapy and radiotherapy effectiveness 7. However, this remains investigational and should not guide current clinical practice.
Safety Profile
Clinical trials report good tolerability with no significant adverse events when used for wound management 6. The safety profile does not differ significantly from NSAIDs when used for pain management 4.
Clinical Algorithm
- For post-surgical wounds: Initiate 2 tablets TID for 7 days starting immediately post-operatively
- For acute inflammation/trauma: Same dosing, assess response at 3-5 days
- For acute hemorrhoids: Consider topical application mixed with heparin ointment
- For postoperative pain: May use as alternative to NSAIDs in comparable doses
The primary limitation is that most supporting evidence comes from small trials in specific surgical contexts, and the drug is not widely used in Western medical practice, limiting generalizability of these findings.